Performs with Jamie Foxx on Wednesday
Related Content
Complete 2008 election coverage
Kanye West's repent on the day Barack Obama was nominated for president: that his mother, Donda, hadn't lived to experience it.
"It's an incredible time to be about. I wish my ma could get seen this day," the rapper told a crowd gathered for his performance early Thursday morning in Denver.
Jamie Foxx then coupled West onstage and delivered what was easily the strangest Obama song dedication at this week's Democratic National Convention.
"We make story, man," Foxx declared at the ONE campaign party. "With Obama, we make history. If you ready for Obama, make some noise. Yo man, let's do this for Obama."
Nobody said politics and amusement always commix smoothly. The pair then launched into their hit "Gold Digger," about money-grubbing women.
The party, sponsored by Bono's ONE anti-poverty hunting expedition and the Recording Industry Association of America, john Drew celebrities including Forest Whitaker and Ashley Judd, world Health Organization arrived with Foxx waving an American flag. Pennsylvania Sen. Bob Casey, former Virginia Gov. Mark Warner and former South Dakota Sen. Tom Daschle too walked the red carpet.
Some, including Daschle, left the club earlier West took the leg and roared through hits such as "Touch the Sky," "Home" and "Stronger."
Backed by a band clad in black outfits that seemed elysian both by Mad Max and the riot law ringing the convention sports stadium, the rap music star as well tried out two new songs he said he'd written in the past several years -- both more focused on relationships and grief than politics.
Thursday 4 September 2008
Monday 25 August 2008
Singer to McCain: Don't Run On My Song
(AP Photo)
Jackson Browne doesn't want John McCain running on anything fueled by his lyrics. The singer-songwriter sued McCain and the Ohio and national Republican committees in U.S. District Court in Los Angeles on Thursday, accusing them of exploitation his song "Running on Empty" without his permission.
The lawsuit claims the song's use was an violation of his copyright and will lead people to conclude he endorses McCain. The suit says Browne is a lifelong giving who is as well-known for his music as for existence "an advocate for social and environmental justice."
The advertizement mocks Democratic presidential nominee Barack Obama's contention that if U.S. drivers got regular tuneups and drove on in good order inflated tires, they could save the same amount of vegetable oil that would be gained by seaward drilling. According to the suit, "Running on Empty" plays in the background of the ad criticizing the remarks.
Robert Bennett, chair of the Ohio party, said the ad was pulled when Browne objected. He called the case a "big to-do around nothing."
McCain spokesman Brian Rogers disavowed the ad, expression it wasn't a product of the Republican presidential candidate's campaign.
Browne's lawsuit contends the Ohio Republican party released the ad on behalf of McCain and the RNC. The RNC did not return a phone call seeking comment.
The suit notes that other musicians, including ABBA and John Cougar Mellencamp, have asked McCain to stop using their work.
Browne's attorney, Lawrence Iser, called the ad's usage of the song "reprehensible."
The 59-year-old isaac Merrit Singer claims his reputation has already been damaged and is quest more than $75,000 in damages.
Browne released "Running on Empty" � the song and an record album by the same name � in 1977. According to the lawsuit, the album has sold more than than 7 million copies.
Browne's financial success has aided Democratic candidates over the years. Campaign finance records show he contributed $2,300 to Obama's presidential campaign net year and $2,000 to the Illinois senator's campaign coffers in 2004.
More info
Friday 15 August 2008
SCOLR Pharma, Inc. Submits Abbreviated New Drug Application For A 12-hour CDT-based Pseudoephedrine Formulation
�Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that 89 pct of surveyed rheumatologists
foresee prescribing Roche/Chugai's Actemra, following the expected
launch of the drug for rheumatoid arthritis in 2009. Surveyed
rheumatologists indicated they would prescribe Actemra, an interleukin-6
inhibitor, to an estimated 10 pct of their patients sise months after
the drug's launch. On July 29, 2008, the Food and Drug Administration's
Arthritis Advisory Committee recommended Actemra's approval for arthritic
arthritis. Although some control board members expressed concern around data that
suggested the potential for negative side effects, the committee indicated
that clinical trials supported Actemra's efficacy.
The new Physician & Payer Forum report, Biologics in Rheumatoid
Arthritis: Physician and Payer Perspective on Recently Launched and
Emerging Biologics in Rheumatoid Arthritis, finds that rheumatologists are
highly receptive to the many new agents expected to plunge by 2011, but
they may human face increasing barriers to reimbursement and modified access to
novel biological agents.
In addition to Actemra, the other rising biologic agents included in
the report survey are UCB's Cimzia, Centocor/Schering-Plough/Mitsubishi
Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab.
The report finds that managed care organizations' (MCO) pharmacy directors
differ on the likelihood of formulary inclusion for paint emerging
biologics as their expectations varied widely in response to whether they
will include these agents on their formularies. Pharmacy directors may be
reserving judgment on key biologic agents until more clinical data becomes
available.
Nevertheless, surveyed rheumatologists remain unswerving in their
preference for TNF-alpha inhibitors over other biologic agents for the
treatment of rheumatoid arthritis. Ninety-nine of 100 surveyed
rheumatologists reported prescribing TNF-alpha inhibitors as first-line
biologic therapy for the disease.
"Most rheumatologists expect the dominance of TNF-alpha inhibitors to
remain, and possibly expand, over the side by side two long time," said Cindy Mundy,
Ph.D., director at Decision Resources. "The forthcoming launches of Cimzia and
golimumab will increase the number of TNF-alpha inhibitors approved for
rheumatoid arthritis from three to five. Following the launches of Cimzia
and golimumab, well-nigh half of surveyed rheumatologists expect to prescribe
trey or more TNF-alpha inhibitors before moving to a different grade of
agents."
Biologics in Rheumatoid Arthritis: Physician and Payer Perspective on
Recently Launched and Emerging Biologics in Rheumatoid Arthritis is based
on a U.S. survey of 100 rheumatologists and 20 MCO drugstore directors.
Their responses were compared to assess similarities and differences of
opinion regarding clinical, economic and scientific factors.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from Decision
Resources that offers access to high volume-prescribing physicians,
specialists, and managed care system representatives in the United
States; depth psychology of events and appraise participants' responses to them;
insight into prescribing patterns; and an examination of the implications
of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader in
grocery research publications, advisory services, and consulting designed to
help clients shape strategy, allocate resources, and master their
world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that 89 pct of surveyed rheumatologists
foresee prescribing Roche/Chugai's Actemra, following the expected
launch of the drug for rheumatoid arthritis in 2009. Surveyed
rheumatologists indicated they would prescribe Actemra, an interleukin-6
inhibitor, to an estimated 10 pct of their patients sise months after
the drug's launch. On July 29, 2008, the Food and Drug Administration's
Arthritis Advisory Committee recommended Actemra's approval for arthritic
arthritis. Although some control board members expressed concern around data that
suggested the potential for negative side effects, the committee indicated
that clinical trials supported Actemra's efficacy.
The new Physician & Payer Forum report, Biologics in Rheumatoid
Arthritis: Physician and Payer Perspective on Recently Launched and
Emerging Biologics in Rheumatoid Arthritis, finds that rheumatologists are
highly receptive to the many new agents expected to plunge by 2011, but
they may human face increasing barriers to reimbursement and modified access to
novel biological agents.
In addition to Actemra, the other rising biologic agents included in
the report survey are UCB's Cimzia, Centocor/Schering-Plough/Mitsubishi
Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab.
The report finds that managed care organizations' (MCO) pharmacy directors
differ on the likelihood of formulary inclusion for paint emerging
biologics as their expectations varied widely in response to whether they
will include these agents on their formularies. Pharmacy directors may be
reserving judgment on key biologic agents until more clinical data becomes
available.
Nevertheless, surveyed rheumatologists remain unswerving in their
preference for TNF-alpha inhibitors over other biologic agents for the
treatment of rheumatoid arthritis. Ninety-nine of 100 surveyed
rheumatologists reported prescribing TNF-alpha inhibitors as first-line
biologic therapy for the disease.
"Most rheumatologists expect the dominance of TNF-alpha inhibitors to
remain, and possibly expand, over the side by side two long time," said Cindy Mundy,
Ph.D., director at Decision Resources. "The forthcoming launches of Cimzia and
golimumab will increase the number of TNF-alpha inhibitors approved for
rheumatoid arthritis from three to five. Following the launches of Cimzia
and golimumab, well-nigh half of surveyed rheumatologists expect to prescribe
trey or more TNF-alpha inhibitors before moving to a different grade of
agents."
Biologics in Rheumatoid Arthritis: Physician and Payer Perspective on
Recently Launched and Emerging Biologics in Rheumatoid Arthritis is based
on a U.S. survey of 100 rheumatologists and 20 MCO drugstore directors.
Their responses were compared to assess similarities and differences of
opinion regarding clinical, economic and scientific factors.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from Decision
Resources that offers access to high volume-prescribing physicians,
specialists, and managed care system representatives in the United
States; depth psychology of events and appraise participants' responses to them;
insight into prescribing patterns; and an examination of the implications
of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader in
grocery research publications, advisory services, and consulting designed to
help clients shape strategy, allocate resources, and master their
Thursday 7 August 2008
The Chipmunks
Artist: The Chipmunks
Genre(s):
Comedy
Discography:
Christmas With the Chipmunks, Vol. 2
Year: 1991
Tracks: 12
Christmas With the Chipmunks, Vol. 1
Year: 1990
Tracks: 12
Friday 27 June 2008
Jack Teagarden Orchestra
Artist: Jack Teagarden Orchestra
Genre(s):
Blues
Discography:
Collection (Boogie Woogie)
Year: 1944
Tracks: 1
Saturday 14 June 2008
Kirsten Dunst 'finds love' in rehab
Actress Kirsten Dunst has apparently found love in rehab, according to reports.
InTouch magazine is reporting that the 25-year-old 'Spider-Man' star is seeing a mystery man at the Cirque Lodge rehabilitation centre in Sundance, Utah.
An insider told the magazine: "The staff have asked the two to separate more than enough. She sits on his lap while smoking cigarettes."
"He has even phoned his mother and asked her to send Kirsten flowers at the facility from him. He is trying to be as romantic as it is possible to be in rehab."
Dunst is not the only celebrity to have embarked on a relationship while at the Utah clinic. Last year, Lindsay Lohan began dating snowboarder Riley Giles when she was at the rehab centre.
InTouch magazine is reporting that the 25-year-old 'Spider-Man' star is seeing a mystery man at the Cirque Lodge rehabilitation centre in Sundance, Utah.
An insider told the magazine: "The staff have asked the two to separate more than enough. She sits on his lap while smoking cigarettes."
"He has even phoned his mother and asked her to send Kirsten flowers at the facility from him. He is trying to be as romantic as it is possible to be in rehab."
Dunst is not the only celebrity to have embarked on a relationship while at the Utah clinic. Last year, Lindsay Lohan began dating snowboarder Riley Giles when she was at the rehab centre.
Sunday 1 June 2008
Myriam Hernandez
Artist: Myriam Hernandez
Genre(s):
Latin
Discography:
Enamorandome
Year: 2007
Tracks: 10
Chilean isaac Bashevis Singer known troughout Latinamerica for her wild-eyed ballads. Myriam Hernández released her starting time record album in 1988 acquiring the hit song dynasty "El guy que yo amo. 1990's Myriam Hernández 2 gave the creative person the chance to sign a carry on with Warner México to consolidate her presence in the music business organization, but the failure of her first base phonograph record under the new shrink all over in recriminations betwixt the isaac Bashevis Singer and the record pronounce, blaming each other for the want of gross revenue. In 1994 Myriam Hernandez' fourth production appeared in book stores all around America. Unfortunetly due to her pregnacy at that time Myriam Hernández decided to shorten her promotional tour, cancelling important dates in the U.S. Sony Music signed her up later on in a quartet records contract. By 1997 The isaac Bashevis Singer met a few well known songwriters such as Monica Naranjo, Armando Manzanero and Eros Ramazotti in preparations for the following record album. Todo El Amor was produced by Humberto Gatica and succesfully released in January 1998 getting the vocal "Huele a Peligro," on the Billboard's Hot Latin Tracks. The same year Myriam Hernández was designated as Best Latin Artist by the Entertainment Critics Association of New York (Champion). In the year 2000 Y Mas was released.
Subscribe to:
Posts (Atom)